Newsroom | 222914 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provi...

RAHWAY, N.J.--(BUSINESS WIRE)--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) cov...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its share...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute die Präsentation umfangreicher Phase-3-Daten bei Patienten mit chronischer lymphatischer Leukämie oder kleinem lymphozytischem Lymphom (CLL/SLL) im Alter von 80 Jahren und älter bekannt. Diese zeigen einen anhaltenden Nutzen von BRUKINSA nach fast 6,5 Jahren Nachbeobachtungszeit und untermauern damit dessen Rolle als grundlegender BTK-Inhib...

CARROLLTON, Ga.--(BUSINESS WIRE)--Tanner Health and Healthliant Ventures partner with InStockRx to eliminate medication waste and ensure every dose is used for treating a patient....

AUSTIN, Texas--(BUSINESS WIRE)--  La PDG de MindWalk (NASDAQ : HYFT), Jennifer Bath, participera à la table ronde organisée par Jones AI Day sur l’avenir de la découverte de médicaments par l’IA, à laquelle partipera Absci (NASDAQ : ABSI), un important fournisseur de services d'IA pour le calcul MindWalk Holdings Corp. (« MindWalk ») (NASDAQ : HYFT), entreprise spécialisée dans l'intelligence artificielle bio-native, a annoncé aujourd'hui que sa PDG, Jennifer Bath, participera à une table ronde...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa multinacional de oncologia, anunciou hoje novos dados de sua principal linha de produtos hematológicos no Congresso da Associação Europeia de Hematologia (EHA) de 2026, em Estocolmo. Os resultados atualizados do tacabrutideg (BGB-16673), um potencial degradador de tirosina quinase de Bruton (BTK) líder de mercado, demonstraram respostas duradouras em pacientes com leucemia linfocít...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日在瑞典斯德哥爾摩舉行的2026年歐洲血液學協會(EHA)大會上公布了其基礎血液學產品線的最新資料。潛在同類最優的布魯頓酪氨酸激酶(BTK)降解劑tacabrutideg (BGB-16673)的更新結果顯示，其在經過預治療的復發/難治性(R/R)慢性淋巴性白血病/小淋巴細胞淋巴瘤(CLL/SLL)病患中展現出持久的反應，且在未接受過BTK抑制劑治療的病患中也觀察到了早期活性。此外，BRUKINSA® (zanubrutinib)與下一代BCL2抑制劑BEQALZI™ (sonrotoclax; ZS)的全口服聯合療法的結果也同步公布，該療法在多種B細胞惡性腫瘤中持續展現出快速、深度且持久的反應。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示： 「BTK抑制重塑了B細胞癌症的治療格局，我們相信降解將是下一個飛躍。在本次EHA大會上，taca...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, oggi ha annunciato nuovi dati provenienti dal suo franchising ematologico di base al Congresso 2026 della European Hematology Association (EHA) a Stoccolma. I risultati aggiornati di tacabrutideg (BGB-16673), un potenziale degradatore della tirosina chinasi di Bruton (BTK) best-in-class, ha dimostrato di dare risposte durature nella leucemia linfatica cronica/linfoma li...